XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.25.3

Goodwill and Other Intangible Assets | 9 Months Ended
--- | ---
Sep. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets Goodwill represents the cost of an acquisition in excess of the fair values assigned to identifiable net assets acquired. The carrying value of Goodwill is as follows:
| Carrying Amount
Beginning balance as of January 1, 2025 | $ | 340,668,927 |
Acquisitions (including measurement period adjustments) (see Note 16) | 16,245,030 |
Balance as of September 30, 2025 | $ | 356,913,957 |
Gross carrying value at September 30, 2025 | $ | 360,578,661 |
Accumulated impairment charges | (3,664,704) |
Net carrying value at September 30, 2025 | $ | 356,913,957 |
In addition to annual impairment testing, which is performed as of the first day of the Company's fourth quarter, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions in determining fair value of goodwill or other intangible assets, thus resulting in the need for interim impairment testing, including long-term revenue growth projections, profitability, discount rates, recent market valuations from transactions by comparable companies, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions. No such events or circumstances that might negatively impact the key assumptions were observed in the third quarter of 2025 and, as such, nothing indicated the need for interim impairment testing. The Company also acquired In-Process Research & Development ("In-Process R & D") as part of the acquisitions of Vaporsens, Inc. ("Vaporsens") and Argil Inc. ("Argil"), each of which has been previously disclosed. The patents and intangible assets and related change in carrying values are set forth in the tables below. As of September 30, 2025:
Other Intangible Assets | Gross | Accumulated Amortization | Net | Assumed Useful Life
Gentex Patents | $ | 39,569,675 |  | $ | (28,567,996) |  | $ | 11,001,679 |  | Various
Other Intangible Assets |  |  |  |
HomeLink® Trade Names and Trademarks | $ | 52,000,000 |  | $ | — |  | $ | 52,000,000 |  | Indefinite
HomeLink® Technology | 180,000,000 |  | (180,000,000) |  | — |  | 12 years
Existing Customer Platforms | 43,000,000 |  | (43,000,000) |  | — |  | 10 years
Exclusive Licensing Agreement | 96,000,000 |  | — |  | 96,000,000 |  | Indefinite
BioCenturion LLC ("BioCenturion") Trade Names and Trademarks | 640,000 |  | (58,667) |  | 581,333 |  | 10 years
BioCenturion Technology | 2,300,000 |  | (175,694) |  | 2,124,306 |  | 12 years
eSight Technology | 12,000,000 |  | (1,916,667) |  | 10,083,333 |  | 12 years
eSight Trade Names and Trademarks | 870,000 |  | (138,958) |  | 731,042 |  | 12 years
BioConnect Trade Names and Trademarks | 873,299 |  | — |  | 873,299 |  | 12 years
BioConnect Developed Technology | 6,549,741 |  | — |  | 6,549,741 |  | 12 years
BioConnect Customer Relationships | 1,746,598 |  | — |  | 1,746,598 |  | 10 years
Vaporsens In-Process R&D | 5,800,000 |  | — |  | 5,800,000 |  | Indefinite
Argil In-Process R&D | 6,278,132 |  | — |  | 6,278,132 |  | Indefinite
Air-Craftglass Technology | 1,507,778 |  | (94,236) |  | 1,413,542 |  | 12 years
Guardian Trade Names | 1,300,000 |  | (135,417) |  | 1,164,583 |  | 12 years
Guardian Technology | 6,800,000 |  | (708,333) |  | 6,091,667 |  | 12 years
Total Other Intangible Assets | $ | 417,665,548 |  | $ | (226,227,972) |  | $ | 191,437,576 |  |
Total Patents & Other Intangible Assets | $ | 457,235,223 |  | $ | (254,795,968) |  | $ | 202,439,255 |  |
As of December 31, 2024:
Other Intangible Assets | Gross | Accumulated Amortization | Net | Assumed Useful Life
Gentex Patents | $ | 39,266,409 |  | $ | (28,137,761) |  | $ | 11,128,648 |  | Various
Other Intangible Assets |  |  |  |
HomeLink® Trade Names and Trademarks | $ | 52,000,000 |  | $ | — |  | $ | 52,000,000 |  | Indefinite
HomeLink® Technology | 180,000,000 |  | (168,750,000) |  | 11,250,000 |  | 12 years
Existing Customer Platforms | 43,000,000 |  | (43,000,000) |  | — |  | 10 years
Exclusive Licensing Agreement | 96,000,000 |  | — |  | 96,000,000 |  | Indefinite
BioCenturion Trade Names and Trademarks | 640,000 |  | — |  | 640,000 |  | 10 years
BioCenturion Technology | 2,300,000 |  | — |  | 2,300,000 |  | 12 years
eSight Technology | 12,000,000 |  | (1,166,667) |  | 10,833,333 |  | 12 years
eSight Trade Names and Trademarks | 870,000 |  | (84,583) |  | 785,417 |  | 12 years
Vaporsens In-Process R&D | 5,800,000 |  | — |  | 5,800,000 |  | Indefinite
Argil In-Process R&D | 6,278,132 |  | — |  | 6,278,132 |  | Indefinite
Air-Craftglass In-Process R&D | 1,507,778 |  | — |  | 1,507,778 |  | Indefinite
Guardian Trade Names | 1,300,000 |  | (54,167) |  | 1,245,833 |  | 12 years
Guardian In-Process R&D | 6,800,000 |  | (283,333) |  | 6,516,667 |  | 12 years
Total Other Intangible Assets | $ | 408,495,910 |  | $ | (213,338,750) |  | $ | 195,157,160 |  |
Total Patents & Other Intangible Assets | $ | 447,762,319 |  | $ | (241,476,511) |  | $ | 206,285,808 |  |
Amortization expense of patents and intangible assets was approximately $4.6 million and $13.9 million during the three and nine months ended September 30, 2025, respectively, compared to approximately $4.5 million and $13.4 million for the three and nine months ended September 30, 2024, respectively. Excluding the impact of any future acquisitions, the Company estimates amortization expense for the remainder of the year ending December 31, 2025 to be approximately $1.3 million, and for each of the years ending December 31, 2026, December 31, 2027, December 31, 2028, and December 31, 2029 to be approximately $4 million.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration